Across North America there is resurgent interest in psychedelic treatments for clinical purposes. Michael Pollan’s seminal How to Change Your Mind is widely credited with reformulating how psychedelic substances—notably psilocybin-are viewed among the general public and the health and wellness community.
A surge in search interest for psilocybin and psychedelic treatments
Following the publication of How to Change Your Mind, companies such as MindMed have emerged to foster the use of psychedelic medicines for the general public. These new classes of psychedelics are being developed to target mental health problems like ADHD and anxiety. Unlike traditional psychedelics, the new class of medications, now in FDA-approved clinical trials, do not have hallucinogenic effects.
With the FDA calling it a “breakthrough therapy” for severe depression and MDD (major depressive disorder) psilocybin is garnering the most attention for its clinical treatment potential. While psilocybin is leading the way, other psychedelics are also being researched for myriad other mental health disorders. Government and private resources are focused on the prospective treatment benefits of psychedelics as opposed to their history of being used primarily for recreational and hallucinogenic purposes.
Promising Research Suggests the Market will Continue to Grow
Researchers at Johns Hopkins are at the forefront of fast tracking the use of the psychedelic drug MDMA for use in treating PTSD. Supported by the David Bronner, the CEO of Dr. Bronner’s Magic Soaps, the industry association MAPS (Multidisciplinary Association for Psychedelic Studies) is intent on getting FDA approval for using MDMA.
Mr. Bronner will also be cross-promoting his soap line with label copy that touts the potential benefits of psychedelics for treating mental health conditions. Creative and collaborative engagement with the public is essential for rebranding psychedelics from their traditional hallucinogenic and experimental stage to the controlled, clinical dosing that researchers are developing.
Mental health providers across North America will soon need to familiarize themselves with the market for psychadellics and determine the capacity to which they should play a role in their service offerings.
Marketing Psychedelics and Psychadelic Treatments
There is a growing need for the marketing and advertising of psychadelic products and treatments. M.Ad has managed more interventional psychiatry advertising accounts than any other agency in North America. We specialize in growing practices that offer interventional psychiatric treatments including psychadelic treatments. We know from experience that marketing and advertising these products and services can be tricky business. The medical industry is padded with a robust cushion of regulations that help protect vulnerable audiences from predatory marketing strategies. These rules are in place for good reason and they should be respected. If a company fails to abide by these rules or works to circumvent them, Google and other search engines will shut down access to their marketing engines. M.Ad is familiar with the ins and outs of these regulations and has designed, developed and grown marketing strategies that deliver tremendous value to our clients without compromising the integrity of their online presence.